Genentech: divarasib cuts risk of death 44% in previously treated KRAS G12C lung cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive pivotal data from Genentech, part of Roche, can support the stock and the group's pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01In the Krascendo 1 study, risk of progression or death fell 42% versus first-generation KRAS G12C inhibitors.
- 02Median overall survival is about 18 months versus 12 months for sotorasib or adagrasib.
- 03No new safety signals were observed and treatment-related adverse events were mainly low grade.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets